Investment Rating - The investment rating for the company is "Accumulate" (maintained) [1] Core Views - The impact of major clients' inventory reduction is weakening, and new business expansion is progressing smoothly [3] - In Q3 2024, the company achieved revenue of 450 million yuan, a year-on-year increase of 55.68%, and a net profit attributable to shareholders of 88.67 million yuan, up 49.91% year-on-year [2] - For the first three quarters of 2024, the company reported revenue of 1.157 billion yuan, a year-on-year increase of 10.86%, and a non-recurring net profit of 258 million yuan, down 14.07% year-on-year [2] - The company's home respiratory machine components business accounted for 64.80% of revenue in 2023, and the negative impact from client inventory reduction is gradually diminishing [2] - The company is successfully expanding into new business areas, providing products and components for over ten global top 100 medical device companies [2] Financial Performance Summary - Revenue projections for 2024-2026 are 1.604 billion yuan, 2.007 billion yuan, and 2.499 billion yuan respectively, with net profits of 362 million yuan, 453 million yuan, and 559 million yuan [3] - The corresponding price-to-earnings (PE) ratios are 30.98, 24.76, and 20.07 [3] - The sales expense ratio for the first three quarters of 2024 was 2.62%, an increase of 0.44% year-on-year, while the management expense ratio was 6.46%, a decrease of 0.50% year-on-year [2] - Research and development expense ratio increased to 8.94%, up 1.28% year-on-year, primarily due to foreign exchange differences and the start of stock incentive expense accruals [2] - The company is engaged in comprehensive and in-depth cooperation with several innovative high-tech medical enterprises in various fields [2]
美好医疗：大客户去库存影响削弱，新业务拓展顺利